SOPHiA GENETICS (SOPH) president’s 761-share tax sale under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA President Ross Muken reported a small open-market sale of 761 Ordinary Shares at a weighted average price of $4.6006 per share. The shares were sold on May 19, 2026 to cover tax withholding obligations from restricted stock units that vested on May 18, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. After the transaction, Muken directly holds 680,911 Ordinary Shares, indicating this was a minor, routine tax-related disposition relative to his overall position.

Insights

Equity compensation analyst

Small, pre-planned tax sale tied to RSU vesting; routine impact.

The transaction involves the sale of 761 Ordinary Shares at a weighted average of $4.6006 to cover tax withholding from restricted stock units that vested on May 18, 2026. Such sales are common when equity awards vest and taxes are due.

The filing notes the sale followed a pre-established Rule 10b5-1(c) trading plan, meaning the timing was predetermined rather than opportunistic. After the sale, Ross Muken still holds 680,911 Ordinary Shares, so the disposition is very small relative to his total direct holdings.

This pattern suggests a routine administrative transaction rather than a change in sentiment. Future Forms 4 may continue to show similar tax-related sales when additional restricted stock units vest, depending on the structure of his compensation program.

Insider Trade Summary 10b5-1

Net Seller: 761 shares ($3,501)

Net Sell 1 txn

Insider Muken Ross

Role President

Sold 761 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	761	$4.6006	$4K

Holdings After Transaction: Ordinary Shares — 680,911 shares (Direct, null)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on May 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.54 to $4.66, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 761 shares Weighted average sale price: $4.6006 per share Post-transaction holdings: 680,911 shares +1 more

4 metrics

Shares sold 761 shares Open-market sale on May 19, 2026

Weighted average sale price $4.6006 per share Ordinary Shares sold to satisfy tax obligations

Post-transaction holdings 680,911 shares Direct Ordinary Share holdings after sale

Sale price range $4.54–$4.66 per share Multiple transactions within this range on May 19, 2026

Key Terms

Rule 10b5-1(c), restricted stock units, weighted average price, Ordinary Shares

4 terms

Rule 10b5-1(c) regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"Represents shares sold by the Reporting Person in the open market"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Muken Ross

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/19/2026		S		761(1)	D	$4.6006(2)	680,911	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on May 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.54 to $4.66, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) President Ross Muken report in this Form 4?

Ross Muken reported selling 761 SOPHiA GENETICS Ordinary Shares at a weighted average price of $4.6006 per share. The sale was tied to tax withholding obligations from recently vested restricted stock units, rather than a discretionary portfolio decision.

Why did Ross Muken sell 761 SOPHiA GENETICS (SOPH) shares?

The filing states the 761 shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units on May 18, 2026. This indicates the sale was an administrative tax event connected to equity compensation, not a standalone investment decision.

How many SOPHiA GENETICS (SOPH) shares does Ross Muken hold after this transaction?

After the transaction, Ross Muken directly holds 680,911 Ordinary Shares of SOPHiA GENETICS. Compared with the 761 shares sold, this shows the reported sale is small relative to his overall direct equity position in the company.

Was the Ross Muken SOPHiA GENETICS (SOPH) share sale pre-planned?

Yes. The filing notes the sales were executed under a pre-established Rule 10b5-1(c) trading plan. Such plans schedule trades in advance, so the timing of this sale was not discretionary and was set before the restricted stock units vested.

What price range were the SOPHiA GENETICS (SOPH) shares sold for in this Form 4?

The weighted average sale price was $4.6006 per share, with individual trades executed between $4.54 and $4.66. The filing notes multiple transactions within this range and offers to provide detailed price breakdowns upon written request to interested parties.

Does Ross Muken’s SOPHiA GENETICS (SOPH) share sale signal a major change in ownership?

The sale does not indicate a major ownership change. Only 761 shares were sold for tax withholding, while 680,911 shares remain directly held. This scale suggests a routine tax-related adjustment rather than a significant reduction in his equity stake.